权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Hematopoietic Stem Cell Transplantation for Young Adults with SCD - DCC

年轻 SCD 患者的造血干细胞移植 - DCC

基本信息

批准号：
9324354
负责人：
MARY EAPEN
金额：
$ 36.11万
依托单位：
MEDICAL COLLEGE OF WISCONSIN
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-09-01 至 2020-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9324354
关键词：
Address Adherence Adolescent and Young Adult Adult Affect African American Age Blood Busulfan Child Childhood Chronic Clinical Clinical Trials Clinical Trials Cooperative Group Clinical Trials Network Collaborations Collection Complement Complex Conduct Clinical Trials Dana-Farber Cancer Institute Data Analyses Data Coordinating Center Data Quality Data Reporting Databases Development Disease Disease-Free Survival Eastern Cooperative Oncology Group Eligibility Determination Enrollment Ensure Funding Future Goals HLA Antigens Healthcare Hematology Hematopoiesis Hematopoietic Stem Cell Transplantation Hemoglobin Human Resources Impaired health Individual Infection Information Dissemination Institutes Knowledge Lead Learning Life Longevity Longitudinal Studies Maintenance Marrow Measures Medical Morbidity - disease rate National Cancer Institute National Heart, Lung, and Blood Institute Organ Outcome Patients Pilot Projects Play Population Protocols documentation Provider Recruitment Activity Regimen Research Research Infrastructure Research Personnel Role Safety Seasons Siblings Sickle Cell Sickle Cell Anemia Supportive care System Techniques Testing Therapeutic Time Toxic effect Transplantation United States Wisconsin arm cohort comparative conditioning data management demographics design experience fludarabine follow-up functional outcomes hematopoietic cell transplantation human leukocyte antigen testing improved improved outcome international center medical schools member phase II trial pilot trial prevent public health relevance statistical center thymocyte young adult

项目摘要

DESCRIPTION (provided by applicant): Supportive health care measures instituted during childhood successfully prevent serious infections and many other life-threatening complications of sickle cell disease (SCD), resulting in improved survival to adulthood. This has, in part, shifted the demographics of SCD to include a growing proportion of young adults with chronic health impairments. While hematopoietic cell transplantation (HCT) has curative potential, very few individuals with SCD are treated by HCT, due in part to the toxicity of this treatment. Recently, advances in Human Leukocyte Antigen (HLA) typing techniques and supportive care have improved outcomes of HCT, particularly after unrelated donor HCT. We have organized an interdisciplinary group of transplant investigators and adult sickle cell providers as well as a daa coordinating center very experienced in the conduct of clinical trials for the BMT clinical trials network to test the hypothesis that HCT from an HLA-identical sibling or unrelated marrow donor with a conditioning regimen of Busulfan, Fludarabine and anti-thymocyte is safe and effective in young adults with severe SCD with a two year event free survival of at least 80%. We have tested the feasibility of recruitment and safety of the conditioning regimen in a pilot study of BMT in adults with SCD. We propose to test this hypothesis in a clinical trial that it wil compare outcomes after HCT to outcomes observed in those who receive standard supportive care, the first comparison of this kind in hemoglobin disorders. We will assign 60 patients age 15-40 years who have an available suitably matched donor to the BMT arm and will contemporaneously enroll 120-140 SCD who do not an available suitable donor to a parallel comparison cohort. We propose to investigate HCT in adults with severe sickle cell disease by the following specific aims: 1. Determine the safety and efficacy of HCT in young adults with severe sickle cell disease. 2. Measure the impact of donor hematopoiesis on functional outcomes and end-organ function. We will establish a long term follow up cohort of all eligible patients for the purpose of future studies of long term impact of HCT on outcome sin SCD. If successful, the proposed comparative clinical trial would be the first to compare HCT and supportive care for SCD, and could broaden the therapeutic opportunities for adults with severe SCD.